We are live on ! Find out more
SCM

Soleus Capital Management Portfolio holdings

AUM $2.47B
1-Year Est. Return 115.63%
This Fund
S&P 500
This Quarter Est. Return
+22.99%
1 Year Est. Return
+115.63%
3 Year Est. Return
+435.52%
5 Year Est. Return
+604.31%
10 Year Est. Return
–
AUM
$758M
AUM Growth
+$569M
Cap. Flow
+$474M
Cap. Flow %
62.53%
Top 10 Hldgs %
80.56%
Holding
85
New
22
Increased
12
Reduced
26
Closed
20

Top Buys

Rank Stock Value
1
BCAB icon
BioAtla
BCAB
+$106M
2
DMRA
Damora Therapeutics, Inc. Ordinary Shares
DMRA
+$22.5M
3
NVTA
Invitae Corporation
NVTA
+$11.7M
4
EXEL icon
Exelixis
EXEL
+$8.18M
5
CCCC icon
C4 Therapeutics
CCCC
+$7.79M

Top Sells

Rank Stock Value
1
OSUR icon
OraSure Technologies
OSUR
+$7.61M
2
QDEL icon
QuidelOrtho
QDEL
+$6.75M
3
IMMU
Immunomedics Inc
IMMU
+$6.49M
4
SRPT icon
Sarepta Therapeutics
SRPT
+$6.48M
5
INBX
Inhibrx, Inc. Common Stock
INBX
+$5.13M

Sector Composition

Rank Sector Weight
1 Healthcare 43.51%
2 Consumer Staples 0.62%
3 Real Estate 0.32%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
QDEL icon
76
QuidelOrtho
QDEL
$838M
– –
-30,751
Closed -$6.75M
SRPT icon
77
Sarepta Therapeutics
SRPT
$1.77B
– –
-46,166
Closed -$6.48M
ZYXI
78
DELISTED
Zynex
ZYXI
– –
-129,852
Closed -$2.06M
AXNX
79
DELISTED
Axonics, Inc. Common Stock
AXNX
– –
-54,089
Closed -$2.76M
HARP
80
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
– –
-4,247
Closed -$722K
ARNA
81
DELISTED
Arena Pharmaceuticals Inc
ARNA
– –
-10,977
Closed -$821K
CNST
82
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
– –
-10,742
Closed -$218K
IMMU
83
DELISTED
Immunomedics Inc
IMMU
– –
-76,268
Closed -$6.49M
1 2 3
4

Similar funds

TW
Trajan Wealth Scottsdale, Arizona $2.48B AUM 17.44% 1-Year Est. Return
M
Mirova Paris, France $2.46B AUM 11.42% 1-Year Est. Return
SG
Sourcerock Group Denver, Colorado $2.48B AUM 72.25% 1-Year Est. Return
FFA
First Foundation Advisors Irvine, California $2.48B AUM 18.56% 1-Year Est. Return
GWM
Greenwich Wealth Management Greenwich, Connecticut $2.45B AUM 39.53% 1-Year Est. Return
Q
QVR San Francisco, California $2.49B AUM 48.58% 1-Year Est. Return
SIM
Stratos Investment Management Beachwood, Ohio $2.49B AUM 17.24% 1-Year Est. Return
QT
Quantbot Technologies New York $2.44B AUM 17.13% 1-Year Est. Return

Soleus Capital Management's Q4 2020 Portfolio in Review

As of Q4 2020, Soleus Capital Management held 85 positions worth $758M, up 302% from $189M the previous quarter. Its ten largest holdings account for 81% of the portfolio.

Soleus Capital Management deployed $474M of net new capital in Q4 2020, opening 22 new positions and adding to 12 existing holdings. Its largest new stake was BioAtla: 63,587 shares worth $108M.

By sector, the portfolio is most concentrated in Healthcare at 44% of assets, down from 94% a quarter earlier, followed by Consumer Staples and Real Estate.

On the sell side, the largest reduction was Inhibrx, Inc. Common Stock, an estimated $5.13M trimmed.

  • Soleus Capital Management's largest Q4 2020 buy was BioAtla: 63,587 shares worth $108M.
  • Soleus Capital Management added most to LYRA THERAPEUTICS INC in Q4 2020, an estimated $3.89M increase.
  • Soleus Capital Management's biggest Q4 2020 reduction was Inhibrx, Inc. Common Stock, cutting an estimated $5.13M.
  • Soleus Capital Management fully exited OraSure Technologies in Q4 2020, selling an estimated $7.61M.
  • Soleus Capital Management's ten largest holdings make up 81% of its $758M portfolio in Q4 2020.
  • Soleus Capital Management opened 22 new positions and closed 20 in Q4 2020.
  • Soleus Capital Management's portfolio value rose 302% quarter-over-quarter to $758M.

Based on Soleus Capital Management's 13F filing for Q4 2020, filed 16 Feb 2021.